May 31 |
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Ser...
|
May 31 |
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
|
May 29 |
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
|
May 22 |
Invivyd Elects Two New Independent Members to its Board of Directors
|
May 13 |
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
May 13 |
Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript
|
May 12 |
With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest
|
May 12 |
Invivyd, Inc. (IVVD) Q1 2024 Earnings Call Transcript
|
May 10 |
Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis
|
May 9 |
Invivyd GAAP EPS of -$0.38 beats by $0.13
|